Publications 2026

  1. Loap P, Buvat I, Crehange G, Kirova Y. Toward genomic personalization of breast cancer radiotherapy: foundations, challenges, and a roadmap for clinical integration. The Breast, in press, 2026.

  2. Pfister C, Harter V, Fontugne J, Allory Y, Culine S; VESPER Trial Investigators. Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. Eur Urol Oncol. S2588-9311(26)00004-0, 2026. DOI: 10.1016/j.euo.2026.01.003.

  3. Seban RD, Lamy C, Cabel L, Roux H, Dias Da Silva I, Djerroudi L, Gorret D, Lalanne AI, Louis D, Milder M, Reyal F, Laas E, Bonneau C, Pouget N, Sablin MP, Pierga JY, Dupain C, Berger F, Buvat I, Bidard FC, Vincent-Salomon A, Le Tourneau C, Alanio C, Lantz O. CMV seropositivity associates with poor clinical outcome in triple negative breast cancer. iScience in press, 2026.

  4. Meng XY, Shi MJ, Li S, Liu M, Fontugne J, Song J, Radvanyi F, Wang FB, Bernard-Pierrot I, Wang XH. Tobacco’s dual genomic footprints in bladder cancer revealed by multi-omics analysis: An SBS4-like LumU-enriched signature and smoking-driven HRD-related genomic instability. Genes & Diseases, in press, 2026. Link to pdf.

  5. Loap P, Buvat I, Fourquet A, Kirova Y, Crehange G. Genomic analysis of radiosensitivity in breast cancer: identifying histopathological and molecular determinants and assessing genomic-adjusted radiation dose for personalized dose escalation. Strahlenther Onkol, 202(2):196-208, 2026. DOI: 10.1007/s00066-025-02454-4